Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Part of paid clinical trials in Anniston, Alabama.
- Sponsor
- Marea Therapeutics
- Study ID
- NCT07028749
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Hypertriglyceridemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- MAR001 — DRUGSubcutaneous Injection
- Placebo — DRUGSubcutaneous injection
Study Details
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of TG in adults with elevated TG and RC.
Key Dates
- First listed
- Jun 19, 2025
- Start date
- Jun 30, 2025
- Status verified
- Aug 2026
- Primary completion
- Nov 30, 2027
- Completion
- Apr 30, 2028
Study Design
- Enrollment
- 316 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: MAR001 Dose 1 (Part A)Subcutaneous injection
- Experimental: MAR001 Dose 2 (Part A)Subcutaneous Injection
- Experimental: MAR001 Dose 3 (Part A)Subcutaneous Injection
- Experimental: MAR001 Dose 4 (Part B)Subcutaneous Injection
Primary Outcome Measure
Primary Endpoint [ Time Frame: 12 weeks ]
Central Contacts
- Matty Hughes415-766-3610
Locations (26)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Marea Site 328 | Anniston | Alabama | 36207 | - |
| Marea Site 329 | Mobile | Alabama | 36608 | - |
| Marea Site 313 | Little Rock | Arkansas | 72204 | - |
| Marea Site 306 | Hamden | Connecticut | 06517 | - |
| Marea Site 302 | Boca Raton | Florida | 33434 | - |
| Marea Site 307 | Port Saint Lucie | Florida | 34952 | - |
| Marea Site 310 | Columbus | Georgia | 31904 | - |
| Marea Site 319 | Peachtree Corners | Georgia | 30092 | - |
| Marea Site 317 | Park Ridge | Illinois | 60068 | - |
| Marea Site 325 | Springfield | Illinois | 62702 | - |
| Marea Site 301 | Louisville | Kentucky | 40213 | - |
| Marea Site 316 | Baltimore | Maryland | 21229 | - |
| Marea Site 330 | Kansas City | Missouri | 64151 | - |
| Marea Site 305 | St Louis | Missouri | 63110 | - |
| Marea Site 304 | Great Neck | New York | 11021 | - |
| Marea Site 318 | New Windsor | New York | 12553 | - |
| Marea Site 303 | Greensboro | North Carolina | 27405 | - |
| Marea Site 315 | Winston-Salem | North Carolina | 27104 | - |
| Marea Site 314 | Greenville | South Carolina | 29607 | - |
| Marea Site 320 | Little River | South Carolina | 29566 | - |
| Marea Site 326 | Memphis | Tennessee | 38119 | - |
| Marea Site 322 | Amarillo | Texas | 79124 | - |
| Marea Site 308 | McKinney | Texas | 75071 | - |
| Marea Site 312 | San Antonio | Texas | 78229 | - |
| Marea Site 321 | Manassas | Virginia | 20109 | - |
| Marea Site 309 | Tacoma | Washington | 98405 | - |
Find similar trials in Anniston, AL
Related Studies
- Phase 1b Study of VERVE-201 in Patients With Refractory HyperlipidemiaPHASE1 · Recruiting · Verve Therapeutics, Inc. · Clearwater, Florida
- Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaPHASE3 · Recruiting · Arrowhead Pharmaceuticals · Bakersfield, California
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasPHASE1 · Recruiting · CRISPR Therapeutics AG · Hialeah, Florida
- A Study to Assess the Safety, Tolerability and Efficacy of ION775PHASE2 · Recruiting · Ionis Pharmaceuticals, Inc. · Lincoln, California